沙利度胺维持治疗对小细胞肺癌患者生存质量的影响  

Effects of Thalidomide on Life Quality in Patients with Small-cell Lung Cancer(SCLC)

作　　者：刘非[1] 赵恩锋[1] 孟祥玲[1] 王国华[1] 史福敏[1] 

机构地区：[1]沧州中西医结合医院肿瘤内科,河北沧州061000

出　　处：《临床误诊误治》2011年第10期7-9,共3页Clinical Misdiagnosis & Mistherapy

摘　　要：目的应用沙利度胺进行小细胞肺癌(SCLC)维持治疗,观察其对患者生存质量的影响。方法将完成规定周期化疗28例SCLC随机分为治疗组和对照组,每组各14例。治疗组应用沙利度胺100 mg/d,连续睡前顿服至少2个疗程(21 d为1个疗程);对照组定期复查随访。结果治疗组和对照组的功能状态Karnofsky评分改善率分别为71.43%和28.57%,两组比较差异无统计学意义(P=0.075);体重增加率为64.29%和28.57%,两组比较差异无统计学意义(P=0.058);两组治疗前后、治疗组治疗前后、对照组治疗前后生活质量(QOL)评分比较,差异均无统计学意义(P>0.05)。治疗组6例出现轻度不良反应,两组均未见严重药物不良反应。结论沙利度胺用于SCLC的维持治疗是安全的,对患者的生存质量无明显影响。Objective To observe the effects of Thalidomide on the life quality of the SCLC patients as a maintenance treatment.Methods A total of 28 SCLC patients undergoing complete circular chemotherapy were randomly divided into treatment group and control group（n=14 in each）.The treatment group was treated with Thalidomide（100 mg/d,in one single dose） before sleep for 2 courses of treatment（21 days as a course）;the control group did not receive any intervention.Regular observations and follow-up were performed in both groups. Results Karnofsky scores in the treatment group and control group were 71.43% and 28.57% respectively,and the differences between the two groups were not significant（P=0.075）.The weight increasing rates were 64.29% and 28.57%,and the difference was not significant（P=0.058）;there was no significant difference in Quality Of Life（QOL） in both groups before and after treatment,and no significant difference between the two groups（P0.05）.6 patients had slight adverse reaction,but no serious adverse events occurred in both groups. Conclusion Thalidomide as a maintenance treatment is safe in patients with SCLC,without affecting the life quality.

关 键 词：肺肿瘤 抗肿瘤药 治疗 生活质量 药物评价 

分 类 号：R734.2[医药卫生—肿瘤] R453.9[医药卫生—临床医学]